Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Sobi — Merger or Acquisition (November 2018)
25 slides from Swedish Orphan Biovitrum Ab's merger presentation, Nov 13, 2018
Slide 1: Sobi to acquire Synagis US rights from AstraZeneca
Sobi™ to acquire Synagis® US rights from AstraZeneca - Creates a platform for global growth Investor Presentation l 13 November 2018
Slide 2: Forward looking statements
Forward looking statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements, including stat
Slide 3: Agenda and presenters
AGENDA PRESENTERS Guido Oelkers Chief Executive Officer and President Introduction Transaction overview Disease and product overview Strategic rationale Henrik Stenqvist Chief Financial Officer Summary CFO Milan Zdravkovic Head of Research & Development and Chief Medical Officer 2
Slide 4: Agenda
AGENDA Introduction Transaction overview Disease and product overview Strategic rationale Summary 3
Slide 5: Sobi's vision is to become global leaders in rare diseases
Sobi’s vision is to become global leaders in rare diseases Further internationalisation and commercialisation of Haemophilia Build Specialty Care Vision as the preferred partner To be recognised as a global leader in providing innovative Strengthen position treatments that transform lives for in the
Slide 6: Strong growth over the past years
Strong growth over the past years Main growth drivers Sobi revenue1 SEK M • Extremely successful Haemophilia North America product sales launch • Kineret strong double-digit growth 8,900-9,0002 Growth opportunities 33% p.a. • Further growth opportunities in 6,511 Haemophilia and penetration and 5,20
Slide 7: Components of the transaction
Components of the transaction MEDI8897 • Perpetual rights to Synagis® (palivizumab) in • Right to participate in 50 per cent of the future the US earnings of the candidate drug MEDI8897 in the US • Synagis, the only approved respiratory syncytial virus (RSV) prophylaxis for high-risk • MEDI8897 is a
Slide 8: The main theses of the transaction
The main theses of the transaction Longitudinal Build a business on the combination of a unique biologic earnings stream with access to the 50% of earnings of a follow on compound in a much broader patient population Synagis connects Synagis is a product that connects with our DNA, meaning with Sobi
Slide 9: The transaction will support three areas of our strategy
The transaction will support three areas of our strategy Develop Strengthen Drive Haemophilia Specialty Expand R&D Penetration Care US business pipeline Swedish Orphan Biovitrum AB (Publ) (SobiTM) 8
Slide 10: Agenda
AGENDA Introduction Transaction overview Disease and product overview Strategic rationale Summary 9
Slide 11: Overview of transaction terms
Overview of transaction terms Upfront USD 1,500 M (SEK 13.6 B) Financing of upfront consideration • USD 1,000 M (SEK 9.1 B) in cash; Fully committed credit facilities in place • 24.2 million newly issued Sobi shares corresponding to a value of USD 500 M (SEK 4.5 B) • Implied AstraZeneca ownership of
Slide 12: Pro forma financial impact
Pro forma financial impact Key Financials Key Financials Combined FY2018E (SEK) LTM 30 June 2018 (SEK) Pro forma Revenues 8.95 billion1 2.4 billion2 11.4 billion EBITA3 Margin 38-39%1 >60% >40% Enhances financial capacity 1. Revised outlook published on 31 October 2018. EBITA expected in the range o
Slide 13: Agenda
AGENDA Introduction Transaction overview Disease and product overview Strategic rationale Summary 12
Slide 14: RSV infection may be associated with significant morbidity
RSV infection may be associated with significant morbidity • Respiratory syncytial virus (RSV) is a major cause of respiratory illness in young children • Almost all children have been infected by 4 years of age • Symptoms may be like common cold and can develop into bronchiolitis and pneumonia • Se
Slide 15: Synagis is the only therapy approved for prevention of serious RSV
Synagis® (palivizumab) is the only therapy approved for the prevention of serious RSV disease in high-risk infants • Recombinant humanised monoclonal ab that provides protection against RSV • Well established safety and efficacy profile • Indicated for prevention of serious lower respiratory tract d
Slide 16: MEDI8897 is an extended half-life anti-RSV F monoclonal antibody
MEDI8897 is an extended half-life anti-RSV F monoclonal antibody • Human antibody against RSV with greater potency than palivizumab in in vitro and pre-clinical models • Engineered to have an extended half-life thereby potentially enabling a single dose to cover an RSV season • Received Fast Track D
Slide 17: Agenda
AGENDA Introduction Transaction overview Disease and product overview Strategic rationale Summary 16
Slide 18: Strategic rationale
Strategic rationale Accelerate build Diversify Sobi’s Enhance up of Sobi’s US revenue base financial commercialisation into Immunology capacity platform 17 Swedish Orphan Biovitrum AB (Publ) (SobiTM)
Slide 19: Diversify revenue base in Specialty Care – Immunology
Diversify revenue base in Specialty Care – Immunology Haemophilia Specialty Care Immunology Gen/Met & Other emapalumab Swedish Orphan Biovitrum AB (Publ) (SobiTM) 18
Slide 20: Diversify Sobi's revenue base into Immunology
Diversify Sobi’s revenue base into Immunology Sobi Specialty Care Portfolio1 • Provides further diversification into Sales in SEK M immunology • Adds important new product with an orphan- like paediatric patient population with a high unmet medical need Gen/Met • Commercial platform enables future n
Slide 21: Transformative to Sobi US
Transformative to Sobi US Pro Forma 2018 total revenue contribution Pre-Transaction Post-Transaction1 North America 14% North America 32% EMENAR + ROW EMENAR + 86% ROW 68% • Well established European sales and • More than doubles US sales marketing platform • Accelerates build up of US commercial pl
Slide 22: Agenda
AGENDA Introduction Transaction overview Disease and product overview Strategic rationale Summary 21
Slide 23: Strategic rationale
Strategic rationale Accelerate build Diversify Sobi’s Enhance up of Sobi’s US revenue base financial commercialisation into Immunology capacity platform 22 Swedish Orphan Biovitrum AB (Publ) (SobiTM)
Slide 24: Q&A
Q&A @sobl
Slide 25: Slide 25